Diapositiva 1

Diapositiva 1

Non servono gli antiaritmici? Prof Luigi Padeletti Universit di Firenze Heart Failure & Co. Caserta, 29-30 aprile 2011 Sommario degli studi sul trattamento farmacologico Studio CAST-I1 Pazienti 1498 Disegno dello studio

Encainide, flecainide/ placebo Risultato Sospeso per numero eccessivo di decessi nel braccio di studio CHF-STAT2 674 Amiodarone/Placebo SWORD3 546

d-sotalolo/Placebo ESVEM4 486 EPS-guidato/Holterguidato EMIAT5 1500 Amiodarone/Placebo Nessuna variazione rispetto alla mortalit globale CAMIAT6

1200 Amiodarone/Placebo Nessuna variazione rispetto alla mortalit globale 1 Echt, et al. N Engl J Med. 1991;324:7818. 2 Singh, et al. N Engl J Med. 1995;333:7782 (supported by Sanofi & Wyeth). 3 Waldo A.L. The Lancet; 1996;348:712. (supported by Bristol-Myers Squibb). Nessuna variazione rispetto alla mortalit globale Sospeso per numero eccessivo di decessi nel braccio di studio Mortalit elevata in ambedue

i bracci 4 Mason J.W. N Engl J Med. 1993;329(7):4528. (Supported by BristolMyers Squibb, Knoll Pharmaceutical, Boehringer-Ingelheim, Parke-Davis, and Ciba-Geigy). 5 Julian D.G. The Lancet. 1997;349:66774.(Supported by Sanofi) 6 Cairns J.A. The Lancet. 1997;349:67582. Implanted Standby Defibrillators In fact, the implanted defibrillator system represents an imperfect solution in search of a plausible and practical application. Bernard Lown and Paul Axelrod Circulation, Volume XLVI, October 1972 Secondary Prevention Trials:

Reduction in Overall Mortality with ICD Therapy % Mortality Reduction w/ ICD Rx 80 60 40 31% 28% 20% 20 0 AVID

1 3 Years The AVID Investigators. N Engl J Med. 1997;337:1576-83. Kuck K. Circ.2000;102:748-54. 3 Connolly S. Circ. 2000;101:1297-1302. 1 2 CASH 2 3 Years CIDS 3

3 Years Secondary Prevention Trials: Reduction in Mortality with ICD Therapy % Mortality Reduction w/ ICD Rx 80 60 40 59% 56% 31%

Overall Death Arrhythmic Death 33% 28% 20% 20 0 AVID 1 3 Years The AVID Investigators. N Engl J Med. 1997;337:1576-83. Kuck K. Circ.2000;102:748-54. 3

Connolly S. Circ. 2000;101:1297-1302. 1 2 CASH 2 3 Years CIDS 3 3 Years Primary Prevention Post-MI Trials: Reduction in Overall Mortality with ICD Therapy % Mortality Reduction w/ ICD Rx 80

60 55% 54% 40 31% 20 0 MADIT 1 27 Months

Moss AJ. N Engl J Med. 1996;335:1933-40. Buxton AE. N Engl J Med. 1999;341:1882-90. 3 Moss AF. N Engl J Med. 2002;346:877-83. 1 2 MUSTT 2 39 Months MADIT-II 20 Months 3 Primary Prevention Post-MI Trials: Reduction in

Mortality with ICD Therapy % Mortality Reduction w/ ICD Rx 80 60 73% 75% Overall Death Arrhythmic Death 61% 55% 54%

40 31% 20 0 MADIT 1 27 Months MUSTT 2 39 Months

MADIT-II 3, 4 20 Months Moss AJ. N Engl J Med. 1996;335:1933-40. Buxton AE. N Engl J Med. 1999;341:1882-90. 3 Moss AF. N Engl J Med. 2002;346:877-83. 4 Moss AJ. Presented before ACC 51st Annual Scientific Sessions, Late Breaking Clinical Trials, March 19, 2002. 1 2 % Mortality Reduction w/ ICD Rx % Mortality Reduction w/ ICD Rx

Reductions in Overall Mortality with ICD Therapy 80 60 54% 55% 40 31% 20 ICD mortality reductions in primary prevention trials are equal to or greater than those in secondary

prevention trials. 0 MADIT 1 MUSTT 2 MADIT-II 27 months 39 months 20 months 3 80

60 40 31% 28% 20% 20 Moss AJ. N Engl J Med. 1996;335:1933-40. Buxton AE. N Engl J Med. 1999;341:1882-90. 3 Moss AJ. N Engl J Med. 2002;346:877-83 4 The AVID Investigators. N Engl J Med. 1997;337:1576-83. 5 Kuck K. Circ. 2000;102:748-54.

6 Connolly S. Circ. 2000:101:1297-1302. 1 0 2 AVID 4 3 Years CASH 5 3 Years CIDS 6 3 Years % Mortality Reduction w/ ICD Rx

% Mortality Reduction w/ ICD Rx Reductions in Mortality with ICD Therapy 80 60 75% 76% Overall Death Arrhythmic Death 61% 55% 54%

40 31% 20 ICD mortality reductions in primary prevention trials are equal to or greater than those in secondary prevention trials. 0 MADIT 1 MUSTT 2 MADIT-II

3, 4 27 months 39 months 20 months 80 60 40 59% 56% 31%

Overall Death Arrhythmic Death 33% 28% 20% 20 Moss AJ. N Engl J Med. 1996;335:1933-40. Buxton AE. N Engl J Med. 1999;341:1882-90. 3 Moss AJ. N Engl J Med. 2002;346:877-83 4 Moss AJ. Presented before ACC 51st Annual Scientific Sessions, Late Breaking Clinical Trials, March 19, 2002. 5

The AVID Investigators. N Engl J Med. 1997;337:1576-83. 6 Kuck K. Circ. 2000;102:748-54. 7 Connolly S. Circ. 2000:101:1297-1302. 1 2 0 AVID 5 3 Years CASH 6 3 Years CIDS 7 3 Years Reason for treatment with AADs in ICD recipients

Prognostic importance of defibrillator shocks in patients with heart failure Benefits of adjuvant AADs in ICD patients Betabloccanti: Effetti sulla mortalit 26 trials > 24.000 pts Post-infarto BETABLOCCANTI PLACEBO RIDUZIONE

Mortalit Totale 934/12438 (7.5%) 1124/11860 (9.5%) - 21% Morte Improvvisa 288/8115 (3.5%) 401/7706 (5.2%) - 33%

YUSUF S. et al. Prog Cardiovas Dis, 1985; 17: 335-371 Clinical Trial summarizing Benefits of AADs Clinical Trial summarizing Benefits of AADs OPTIC Trial Side Effects of Beta-Blockers could be Beneficial Conclusions Adjunctive AAD therapy often is necessary in many patients with ICDs for control of recurrent ventricular tachyarrhythmias and prevention of ICD

shocks. Conclusions Given the scarsity of safe and effective AADs for this indication, the decision of when to start an AAD in the patient with an ICD must be individualized. Conclusions If AAD therapy is initiated, the potential for drug-related toxicities and device interactions must be recognized and anticipated.

Recently Viewed Presentations

  • Colt

    Colt

    Managed networking, Ethernet, IPVPN. SDH (now <8% of total NS revenue) Value proposition. Combination of local depth and international breadth means we can provide appropriate solutions from basic point-to-point services and internet access to end-to-end managed network solutions.
  • Thermal Stratification - MTU

    Thermal Stratification - MTU

    Thermal Stratification Seasonal Stratification Thin ice? ... C C C C C O O O O O O O O O O O O C C C O O O O P P + O O O O C C...
  • Add Structure to your Teaching

    Add Structure to your Teaching

    Capitalizes on strength in visuospatial skills (Quill, 1997) and attention to visual information (Garretson, Fein, & Waterhouse, 1990) Assist. Assist with increases in independence; decreased reliance on prompts (Green, 2001) Reduce. Reduce anxiety and increase flexibility
  • Chemical Messengers - Weebly

    Chemical Messengers - Weebly

    The movement of small molecules through gap junctions metabolically couples the cells and causes cells of organs to act as a unit. Chemical messengers Ligands (from secretory cell) are secreted in the interstitial fluid target cells respond by receptors that...
  • The History of Unions in the US Class 1: Origins

    The History of Unions in the US Class 1: Origins

    Gunner's Mate Yogi. After his one season with the Tars, Yogi became a tar of a different sort - joining the Navy . ... Former Senators manager Bucky Harris skippered the club. After the War - Coming to the Yankees....
  • Grand Rounds Jinghua Chen, MD, PhD October 21,

    Grand Rounds Jinghua Chen, MD, PhD October 21,

    Multiple evanescent white dot syndrome. Multifocal choroiditis and panuveitis ( MCP ) Acute posterior multifocal placoid pigment epitheliopathy (APMPPE) Birdshot chorioretinopathy. Punctate inner choroidopathy(PIC) White Dot Syndromes (WDS) a collection of diseases characterized by localized,circumscribed whitish lesions in the RPE...
  • Revision methods Type  Revision App into the App

    Revision methods Type Revision App into the App

    Type 'Revision App' into the App Store. This is free! Type 'BPC English' into YouTube Type 'BPC English' into Facebook
  • Baptism of the Holy Spirit

    Baptism of the Holy Spirit

    William Miller - a Baptist farmer and lay-preacher. Each had the same essential ingredients of truth: Sacrifice. Daily ministry. Justice and mercy. Baptism of the Holy Spirit"Did you receive the Holy Spirit when you first believed?" Acts 19:2.